- Home
- CRBP vs STRW Comparison
CRBP vs STRW Comparison
Compare CRBP & STRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRBP | STRW |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.3M | 151.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CRBP | STRW |
|---|---|---|
| Price | $7.86 | $12.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $50.29 | $12.72 |
| AVG Volume (30 Days) | ★ 492.2K | 28.8K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 4.93% |
| EPS Growth | N/A | ★ 19.41 |
| EPS | N/A | ★ 0.61 |
| Revenue | N/A | ★ $145,392,000.00 |
| Revenue This Year | N/A | $35.42 |
| Revenue Next Year | $100.00 | $7.19 |
| P/E Ratio | ★ N/A | $21.36 |
| Revenue Growth | N/A | ★ 29.76 |
| 52 Week Low | $4.64 | $8.70 |
| 52 Week High | $20.56 | $14.00 |
Technical Indicators
Market Signals| Indicator | CRBP | STRW |
|---|---|---|
| Relative Strength Index (RSI) | 28.92 | 50.36 |
| Support Level | $7.97 | $12.84 |
| Resistance Level | $8.54 | $13.35 |
| Average True Range (ATR) | 0.47 | 0.43 |
| MACD | 0.04 | -0.06 |
| Stochastic Oscillator | 5.21 | 21.43 |
Price Performance
Historical ComparisonAbout CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About STRW Strawberry Fields REIT Inc.
Strawberry Fields REIT Inc is a self-managed and self-administered company that specializes in the acquisition, ownership and triple-net leasing of skilled nursing facilities and other post-acute healthcare properties.